";s:4:"text";s:3659:" Positive Outlook. Still, the company now seems to have more than enough capital to fund its operations for at least a year without diluting its shareholders' positions.Stock Advisor launched in February of 2002.
Disease doesn’t discriminate by race, but health and economicFirst reported consecutive in vivo gene knockout and insertion achieves therapeutically relevant results in an alpha-1 antitrypsin deficiency mouse...Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks(Biotech stocks that hit 52-week highs on May 20.) The company should submit an IND application for NTLA-2001 soon. Comp & Benefits. Do the numbers hold clues to what lies ahead for the stock?As of June 2017, Yahoo Finance is part of Verizon Media, the media division of Verizon Communications. It is the largest business news web site in the United States by monthly traffic.Race is not a topic that often comes up in pharmaceutical discussions but perhaps it should. Intellia Therapeutics (NASDAQ:NTLA) is a biotech company that focuses on gene editing, a relatively new technology that could allow scientists to devise … Current Employee - Senior Manager. Work/Life Balance. 3.56 Employees say 0.00 Applicants say Intellia Therapeutics 31.Jan 2019. The company is going after diseases including hemophilia, a rare condition characterized by abnormal blood clotting, and sickle cell disease (SCD), a disorder that leads to crescent-shaped red blood cells. Senior Management. The company has partnerships with Novartis and Regeneron.Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks(Biotech Stocks Hitting 52-week Highs May 19) ADC ...On Tuesday, 118 companies set new 52-week highs.Interesting Highlights: Facebook (NASDAQ: FB) was the largest firm by market cap to set a new ...Intellia Therapeutics Inc (NTLA) delivered earnings and revenue surprises of -61.54% and -46.14%, respectively, for the quarter ended March 2020. Intellia Therapeutics Reviews. In June, Intellia raised approximately $115 million (in gross proceeds) in a public offering of common stock. I have been working at Intellia Therapeutics … Recommends . May 28, 2020 "Promising Biotech Company- Unique and Diverse Scientific Platform!" Star Star Star Star Star. Intellia currently has about 10 products in its pipeline. Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna (with colleagues at University of California) and Virginijus Šikšnys (with colleagues at Vilnius University). Culture & Values. Intellia's second most advanced pipeline candidate is NTLA-2001, a potential treatment for transthyretin amyloidosis. Intellia's most advanced pipeline candidate is OTQ923, its potential SCD treatment. 3.56 3.56 Suggestions for improvement.